It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 1 of 46

1	Research ethics review during the COVID-19 pandemic:
2	An international study
3	
4	
5	Fabio Salamanca-Buentello ¹ , Rachel Katz ² , Diego S. Silva ³ , Ross E.G. Upshur ^{1,4} , and Maxwell J.
6	Smith ⁵
7	
8	
9 10 11 12 13 14 15 16	 Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada Institute for the History and Philosophy of Science and Technology, University of Toronto, Toronto, Canada School of Public Health, The University of Sydney, Sydney, Australia Dalla Lana School of Public Health, University of Toronto, Toronto, Canada Faculty of Health Sciences, Western University, London, Canada
17	
18	Corresponding Author:
19 20 21 22 23 24 25 26 27 28	Maxwell J. Smith, PhD Assistant Professor School of Health Studies Faculty of Health Sciences Western University Room 331, Arthur and Sonia Labatt Health Sciences Building Phone: 519 661-2111 x88589 Email: maxwell.smith@uwo.ca ORCID: 0000-0001-5230-0548

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 2 of 46

29 Author contributions:

30

31 Fabio Salamanca-Buentello

32 Conceptualization, formal analysis, investigation, methodology, visualization, and writing (original33 draft).

34

35

36 Rachel Katz

- 37 Conceptualization, writing (review and editing).
- 38 39

40 **Diego S. Silva**

- 41 Conceptualization, funding acquisition, methodology, validation, and writing (review and editing).
- 42

43

44 Ross E.G. Upshur

Conceptualization, formal analysis, funding acquisition, investigation, methodology, supervision, and
 writing (review and editing).

47 48

49 Maxwell J. Smith

- 50 Conceptualization, funding acquisition, investigation, methodology, project administration, resources,
- 51 supervision, validation, and writing (review and editing).

It is made available under a CC-BY 4.0 International license . Research ethics review during the COVID-19 pandemic: An international study

Page **3** of **46**

53 ABSTRACT

54

55	Research ethics review committees (ERCs) worldwide faced daunting challenges during the
56	COVID-19 pandemic. There was a need to balance rapid turnaround with rigorous evaluation of high-
57	risk research protocols in the context of considerable uncertainty. This study explored the experiences
58	and performance of ERCs during the pandemic.
59	
60	We conducted an anonymous, cross-sectional, global online survey of chairs (or their delegates) of
61	ERCs who were involved in the review of COVID-19-related research protocols after March 2020. The
62	survey ran from October 2022 to February 2023 and consisted of 50 items, with opportunities for open
63	text responses.
64	
65	Two hundred and three participants [130 from high-income countries (HICs) and 73 from low- and
66	middle-income countries (LMICs)] completed our survey. Respondents came from diverse entities and
67	organizations from 48 countries (19 HICs and 29 LMICs) in all World Health Organization regions.
68	Responses show little of the increased global funding for COVID-19 research was allotted to the
69	operation of ERCs. Few ERCs had pre-existing internal policies to address operation during public
70	health emergencies, but almost half used existing guidelines. Most ERCs modified existing procedures
71	or designed and implemented new ones but had not evaluated the success of these changes. Participants
72	overwhelmingly endorsed permanently implementing several of them. Few ERCs added new members

but non-member experts were consulted; quorum was generally achieved. Collaboration among ERCs

vas infrequent, but reviews conducted by external ERCs were recognized and validated. Review

volume increased during the pandemic, with COVID-19-related studies being prioritized. Most

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 4 of 46

- 76 protocol reviews were reported as taking less than three weeks. One-third of respondents reported
- external pressure on their ERCs from different stakeholders to approve or reject specific COVID-19-
- 78 related protocols.
- 79
- 80 ERC members faced significant challenges to keep their committees functioning during the pandemic.
- 81 Our findings can inform ERC approaches towards future public health emergencies. To our knowledge,
- 82 this is the first international, COVID-19-related study of its kind.
- 83
- 84
- 85

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 5 of 46

86 INTRODUCTION

87

88	The ethical review of research protocols during public health emergencies (PHEs) such as the
89	COVID-19 pandemic is a daunting task. Committees tasked with assessing the ethical acceptability of
90	research projects, which we refer to as ethics review committees (ERCs) but are also variably called
91	research ethics boards, research ethics committees, ethics review boards, and institutional review
92	boards, face challenges to reviewing research protocols swiftly while maintaining a high degree of
93	rigour, all under suboptimal conditions and uncertainty. ERCs must balance the urge for rapid
94	turnaround and flexibility with the requirement for intense scrutiny given that new projects often
95	propose innovative but high-risk diagnostic, therapeutic, or preventive approaches to address the PHE.
96	This is especially challenging in the case of countries with fragile health systems, poor infrastructure,
97	and little experience conducting medical research, as well as countries experiencing protracted
98	emergencies [1-5].

99

100 Failure to ensure rigour and depth during rapid ethics reviews in public health emergencies may place 101 research participants at risk [6]. In such challenging circumstances, ERCs must consider how 102 interventions, study design, eligibility criteria, community engagement, and approaches to vulnerable 103 populations impact scientific validity, participant autonomy, respect for persons, welfare, justice, and 104 social value [2,7–9]. Additional demands on ERCs may include the ability to incorporate and respond 105 swiftly to newly available knowledge, provide monitoring and oversight of research, and considerations 106 of the impact of the PHE on those involved in the research process, such as research participants, 107 investigators, and ERC members and staff [7].

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 6 of 46

109	Public health emergencies force ERCs to make reasonable adjustments and design innovative strategies
110	to address the various components of research ethics review while still adhering to ethical principles
111	[3,6,7,10]. Moreover, after a PHE, changes implemented to secure continued operations of ERCs must
112	be evaluated to determine their success and whether they should be permanently put in place to
113	improve the everyday functioning of the committees.
114	
115	Given the challenges that ERCs worldwide have faced during the COVID-19 pandemic, we aimed in
116	this exploratory study to identify their experiences in the attempt to adapt to this PHE. We were
117	particularly interested in the availability of pandemic-specific support, the promptness of protocol
118	review, the volume of protocols received, the modifications to and innovations in operational
119	procedures and policies and the evaluation of their outcomes, the anticipated permanence of such
120	changes beyond the pandemic, the presence of pressure from different stakeholders on ERCs, the
121	efforts to ensure quorum, the changes to the composition of ERCs, and the approaches to strengthen
122	inter-ERC collaboration. To our knowledge, this is the first international, COVID-19-related study of
123	its kind.
124	
125	
126	METHODS
127	
128	This international, cross-sectional, exploratory online survey was conducted by researchers
129	from Western University, the University of Toronto, and the Lunenfeld – Tanenbaum Research
130	Institute in Canada, and the University of Sydney in Australia, in collaboration with the World Health
131	Organization's COVID-19 Ethics and Governance Working Group.

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 7 of 46

132

133 Inclusion criteria

- We used targeted purposive and criterion sampling to invite Chairs and members of ERCs who were actively involved in the ethics review of COVID-19 research protocols to participate in this study. To ensure eligibility of participants, the first question of the survey asked respondents to confirm whether they had reviewed COVID-19-related research protocols during the pandemic. Responding to our survey was entirely voluntary. For the purposes of this study, we considered March 2020 as the
- 139 beginning of this PHE. We specifically targeted individuals from all WHO regions. Participants were
- 140 assigned to either of two categories: high-income countries (HICs) or low- and middle-income
- 141 countries (LMICs), according to their reported country of residence. To do this, we used the World
- 142 Bank classification of countries (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-
- 143 world-bank-country-and-lending-groups), which is based on gross national income per capita. We
- 144 adopted this widely-used categorization notwithstanding its limitations in terms of hiding power
- 145 imbalances and reducing important differences to questions of economics [11].

146

147 Survey questionnaire

The complete questionnaire is available as **S1 Appendix**. The overall structure and flow of the survey questionnaire, which consisted of a main "trunk" of 37 items organized into 11 thematic categories, is shown in **Error! Reference source not found.** Eight of these items branched into different survey flow elements based on respondents' answers. Thus, in total, the questionnaire, written in English, included 50 questions. We privileged close-ended over open-ended questions, but we allowed respondents the opportunity to provide additional comments for some items. We pilot-tested the online

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 8 of 46

154	questionnaire with a small group of experts who fulfilled the inclusion criteria. This helped polish the
155	wording of the questions and also assess and improve the logistics of the administration of the survey.
156	

- 157 < Fig. 1. Overall structure and flow of the survey questionnaire >
- 158

159 Data collection

160 The invitation to participate in the survey explained the nature and purpose of our study, the inclusion

161 criteria used to select participants, a summary of the procedures involved, and the URL link to the

survey. These invitations were initially distributed by email by the WHO's COVID-19 Ethics and

163 Governance Working Group through the email listserv of the 13th Global Summit of National Ethics

164 Committees (an event that took place in September 2022). The Working Group identified additional

165 potential participants among its extensive contact networks. We also circulated the invitation to experts

166 identified by the research team. Invitations could also be forwarded to individuals designated by ERCs.

167 In both cases, those invited fulfilled our inclusion criteria.

168

Our survey was active from October 11, 2022, to February 28, 2023. We used the Qualtrics Experience
Management (XM) online platform to administer the questionnaire, which was open only to individuals
who received the invitation with the link to the survey.

172

173 Data analysis

The analysis of the findings of this exploratory study employed descriptive statistics and stratified the comparison between responses of participants from HICs with those of participants from LMICs. To facilitate the examination of the results, tables were prepared showing the number and percentage of

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 9 of 46

- 177 respondents from HICs and LMICs who answered each question in the survey. Qualitative data (text
- 178 responses from open-ended questions) were evaluated using thematic analysis and the constant
- 179 comparative method.
- 180

181 **Research ethics approval**

- 182 Our study received approval from Western University's Non-Medical Research Ethics Board (Protocol
- 183 ID 120455). Additionally, it was evaluated by the World Health Organization Research Ethics Review
- 184 Committee (Protocol ID CERC.0181) and was exempted from further review. The use of the Qualtrics
- 185 platform facilitated data collection and management while respecting the privacy and confidentiality of
- 186 participants. Respondents indicated their consent to participate in our survey by selecting a button
- 187 labelled "I consent" at the end of the letter of information and consent, which appeared on the first page
- 188 of the questionnaire. Responses were anonymous to protect participants' privacy and confidentiality
- and encourage the open sharing of experiences.
- 190
- 191

192 **RESULTS**

193

194 Characterization of survey respondents

Two hundred and eighty-one individuals opened our survey. Of these, 250 answered the first question, which confirmed whether respondents fulfilled our inclusion criteria, and with which we could confirm their eligibility. Forty-three individuals explicitly indicated that they did not meet our criteria. Thus, the initial number of suitable respondents was 207. As expected in surveys such as ours

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 10 of 46

- in which participants are allowed to skip questions, the number of respondents per question variedslightly, from a maximum of 207 to a minimum of 147.
- 201
- 202 Of the 204 participants who indicated their sex / gender, 120(58.8%) were female, 82(40.2%) were male, one (0.5%) preferred to self-describe, and one (0.5%) preferred not to disclose this information 203 (Box 1, Table a). The proportion of females was higher in HICs (64.9%) than in LMICs (47.9%); thus, 204 205 the distribution of respondents by sex / gender was more balanced in LMICs than in HICs. As shown in 206 Box 1, Table b, more than three quarters of respondents (77.9%) were 45 years old or older. This was 207 true for both HICs and LMICs. Most respondents provided ethics review for national bodies, such as 208 national ethics committees or national public health organizations; more than a quarter participated in 209 ERCs linked to academic or research institutions (**Box 1, Table c**). However, while almost half of 210 respondents from HICs were members of ERCs affiliated with national bodies, only one quarter of 211 participants from LMICs provided ethics review for such organizations. In contrast, in LMICs, 40% of 212 respondents were members of ERCs associated with academic or research institutions. Furthermore, 213 only 20% of participants from LMICs and 13.9% of participants from HICs provided ethics review for 214 health care facilities.
- 215
- 216

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 11 of 46

217 **Box 1.** Characterization of survey participants

 Table a. Sex / gender of participants

	HICs		LM	ICs	TOTAL		
	n %		n	%	n	%	
Female	85	64.9	35	47.9	120	58.8	
Male	44	33.6	38	52.1	82	40.2	
Prefer to self-describe	1	0.8	0	0.0	1	0.5	
Prefer not to disclose	1	0.8	0	0.0	1	0.5	
TOTAL	131	100.0	73	100.0	204	100.0	

Table b. Age of participants

	HICs		LMICs		тот	AL
	n	%	n	%	n	%
25 - 34 years old	10	7.6	6	8.2	16	7.8
35 - 44 years old	13	9.9	16	21.9	29	14.2
45 - 54 years old	28	21.4	22	30.0	50	24.5
55 - 64 years old	31	23.7	18	25.0	49	24.0
65+ years old	47	35.9	10	13.7	57	27.9
Prefer not to disclose	2	1.5	1	1.4	3	1.5
TOTAL	131	100.0	73	100.0	204	100.0

Table c. Type of organization for which ethics review was provided

	HIC	HICs		LMICs		AL
	n	%	n	%	n	%
National body	89	44.3	24	25.3	113	38.2
Academic institution or research institute	40	19.9	38	40.0	78	26.4
Health care facility	28	13.9	19	20.0	47	15.9
Private industry	16	8.0	5	5.3	21	7.1
Non-governmental organization	9	4.5	4	4.2	13	4.4
Sub-national governmental body	9	4.5	2	2.1	11	3.7
Ethics review committee not linked to another institution / organization	6	3.0	0	0.0	6	2.0
Other	4	2.0	3	3.2	7	2.4
TOTAL	201	100.0	95	100	296	100.0

Note: For this question, respondents could select more than one category. Therefore, "totals" refer to number of selections, not respondents

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 12 of 46

- 219 In terms of the WHO region for which ethics review was provided, all regions were represented in our
- survey (Table S 1). More than one third of respondents reviewed research protocols from Europe,
- almost one fifth from the Americas, one tenth from Africa, and less than one tenth each from the other
- WHO regions.
- 223
- Table 1 shows the number of respondents by country of residence. Participants from 48 countries (19
- HICs and 29 LMICs) responded to our survey. Of the 203 individuals who indicated their country of
- residence, 130 (64%) were from HICs and 73 (36%) from LMICs. There was a large contingent of
- respondents from the UK (93).
- 228
- 229

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 13 of 46

Table 1. Number of respondents by country of residence

232

Total number of countries: 48 Total number of respondents who indicated country of residence: 203 **Respondents from 19 high-income** Respondents from 29 low- and middlecountries (HICs) income countries (LMICs) Australia 1 Angola 1 6 Barbados 1 Argentina 2 Belgium Bangladesh 1 Brunei Darussalam 1 Brazil 4 3 Canada Cameroon 1 2 Chile Colombia 1 Estonia 1 Costa Rica 2 France 1 Ecuador 1 1 Hungary 1 Egypt Italy El Salvador 2 1 2 Latvia 1 Ethiopia New Zealand 1 1 Ghana 1 Grenada 2 Panama 5 Portugal Honduras 1 San Marino 1 India 6 6 Indonesia Singapore 1 South Korea 2 Iran 2 United Kingdom 93 3 Kenva United States 6 Lebanon 1 Liberia 1 2 Malawi 8 Malaysia 8 Mexico Morocco 1 Mozambique 1 Pakistan 4 Saint Vincent and the Grenadines 1 South Africa 6 Uganda 2 TOTAL TOTAL 130 73

233 234

It is made available under a CC-BY 4.0 International license . Research ethics review during the COVID-19 pandemic: An international study

Page 14 of 46

236

- Two thirds of respondents had six or more years of experience as ERC members. This is true for
 participants from both HICs and LMICs (Table S 2).
- 239

As shown in **Table S 3**, about one half of respondents (52%) were involved in only one ERC. This pattern was common for participants from HICs and LMICs. However, more than one third of respondents from HICs participated in three or more ERCs during the COVID-19 pandemic. Of those who indicated involvement with multiple ERCs, close to one half specified that such participation was simultaneous (**Table S 4**).

245

246 Support for the operation of ERCs during the pandemic

247 As shown in **Table S 5**, an overwhelming majority (78.4%) of respondents indicated that their ERCs 248 received no additional support for the operation of their committees during the pandemic. This lack of 249 support was more pronounced in the case of ERCs in LMICs. For the minority of ERCs that did receive 250 support, this consisted mainly of administrative and human resources, with one quarter of respondents 251 from LMICs stating that their ERCs also received financial support, in contrast to only 12.5% of those from HICs (Table S 6). In terms of specific areas supported, participants from both HICs and LMICs 252 253 mentioned teleconferencing and virtual meeting capabilities, information technology, support staff, 254 assistance for ERC reviewers, and training of ERC members (Table 2). Interestingly, while 20% of 255 respondents from HICs chose ERC support staff as one of the areas that received assistance, only 7.5% 256 of those from LMICs did.

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 15 of 46

258

259 **Table 2.** Areas that received additional support during the COVID-19 pandemic

260

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
Teleconferencing and virtual meeting capabilities	23	28.0	8	20.0	31	25.4
Ethics committee support staff	16	19.5	3	7.5	19	15.6
Information technology (IT) support	12	14.6	6	15.0	18	14.8
Ethics committee reviewers	10	12.2	6	15.0	16	13.1
Training of ethics committee members	9	11.0	6	15.0	15	12.3
Other administrative costs	4	4.9	5	12.5	9	7.4
Security for ethics committee members	5	6.1	1	2.5	6	4.9
External experts	1	1.2	4	10.0	5	4.1
Data management and storage	1	1.2	1	2.5	2	1.6
Other	1	1.2	0	0.0	1	0.8
TOTAL	82	100.0	40	100.0	122	100.0

261

262

Note: For this question, respondents could select more than one category. Therefore, "totals" refer 263 to number of selections, not respondents

264

In their text answers, participants alluded to support for covering the costs of using online platforms for 265 266 meetings and protocol review, and for acquiring or upgrading hardware such as laptops and webcams. 267 In one ERC, members were able to claim costs of setting up teleconferencing and of telephone calls if 268 dialling into a meeting. In other ERCs, information technology training was offered, along with 269 technical support for the use of online platforms. It is important to note that almost half of respondents 270 from HICs, but close to the totality (91.4%) of those from LMICs, indicated that their ERCs lacked any 271 pre-pandemic financial planning that included provisions for the support of the committees during a public health emergency (Table S 7). 272 273 274

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 16 of 46

276 Modification of existing procedures or policies

- 277 Respondents from both HICs and LMICs overwhelmingly (more than 75% of participants in both
- 278 cases) reported that their ERCs modified existing procedures or policies to operate during the pandemic
- 279 (**Table S 8**). The most frequently modified domain was meeting logistics, followed by meeting
- 280 frequency and procedures for protocol review and approval (Table S 9).

281

282 In terms of modifications to review procedures, several participants pointed out in their text responses 283 that their ERCs fast-tracked the review of pandemic-related studies, shortening the timeline to review 284 and approve protocols. ERC members were expected to complete the review of these protocols within a 285 few days and, in some cases, 24 hours. To facilitate such a quick turnaround, some ERCs created 286 special sub-committees that would conduct very fast protocol review. Moreover, participants emphasized the importance of simplifying and increasing the flexibility of administrative processes. 287 288 For example, several respondents indicated that their ERCs switched entirely to the use of online 289 platforms for protocol review, eliminating the need for paper documents. 290 291 Numerous participants stated that all ERC meetings were conducted virtually (as opposed to face-to-292 face) during the pandemic, which, in their view, enabled ERC members and researchers to participate

regardless of geographical location, prevented contagion, and allowed rapid turnaround of reviews.

Even in the case of virtual sessions, all other full meeting requirements such as quorum had to be met.

Some ERCs modified their meetings to open a permanent slot in their agendas for COVID-19-related

296 research or added urgent full meetings to discuss top-priority pandemic-related trial protocols. In other

297 cases, members were permanently available to review COVID-19-related protocols, with those

298 pertaining to other topics addressed less frequently.

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 17 of 46

300	While most respondents acknowledged the advantages of using online platforms during the pandemic
301	to organize ERC meetings and to review research protocols, several participants highlighted the
302	challenges that the use of such technologies entailed, particularly for new and more senior members of
303	the ERCs who felt uncomfortable using these platforms. Some individuals deplored the loss of quality
304	in the dynamics among ERC members (stilted conversations, fewer informal interactions) compared
305	against the benefits of face-to-face meetings. Resistance to working online for some was compounded
306	by difficulties accessing the internet and the lack of adequate electronic devices to do so.
307	
308	Regarding the modification of protocol requirements, respondents mentioned the need to add safety
309	procedures for study participants and members of the research teams, facilitating remote documentation
310	of consent, and changing the policies regarding the use of non-anonymized data from health service
311	and public health records for the duration of the pandemic to allow more unrestrained use of data.
312	Some ERCs transitioned from requiring the physical signature of conflict-of-interest declaration forms
313	to an email declaration.
314	
315	As shown in Table 3 , only a minority of respondents indicated that their ERCs conducted a formal
316	evaluation of the success or failure of modifying existing procedures or policies (28% of participants
317	from HICs and 17% of those from LMICs). More than one quarter of respondents did not know
318	whether such modifications had been assessed.
319	
320	
321	

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 18 of 46

3							
	HICs	HICs		S	TOTAL		
	n	%	n	%	n	%	
Yes	24	27.9	8	17.0	32	24.1	
No	36	41.9	29	61.7	65	48.9	
Unsure	26	30.2	10	21.3	36	27.1	
TOTAL	86	100.0	47	100.0	133	100.0	

Table 3. Evaluation of the success / failure of modifying existing procedures or policies

326 Design and implementation of new procedures and policies

Almost two-thirds of respondents from both HICs and LMICs reported that their ERCs had designed and implemented new procedures and policies to address the challenges brought about by the pandemic (**Table S 10**). As in the case of modifications to ERC processes, innovations occurred mainly in the areas of meeting logistics and frequency, and procedures for protocol review and approval (**Table S 11**). This was the case for ERCs in both HICs and LMICs.

332

In their text responses, participants mentioned the development and implementation of new standard operating procedures (SOPs) and the integration of *ad hoc* committees, some including specialists, for urgent, accelerated protocol review. Such fast-track ERCs could review studies in one or two days, considerably shortening the time to complete reviews. One respondent considered the most successful innovation to be the formation of a "pool" of committee members ready to be convened at very short notice to quickly review COVID-19-related protocols. Such an *ad hoc* committee enabled applications to be reviewed and turned around very quickly.

³²⁴

³²⁵

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 19 of 46

341	The proportion of ERCs that formally evaluated the success or failure of new procedures and policies
342	was analogous to that described for modifications to SOPs. Table 4 shows that just 37% of respondents
343	from HICs and 21% of those from LMICs reported that their ERCs conducted such an evaluation.
344	

Table 4. Evaluation of the success / failure of designing and implementing new procedures or policies

	HICs		LMIC	Cs	TOTAI	TOTAL		
	n	%	n	%	n	%		
Yes	25	37.3	8	21.6	33	31.7		
No	26	38.8	26	70.3	52	50.0		
Unsure	16	23.9	3	8.1	19	18.3		
TOTAL	67	100.0	37	100.0	104	100.0		

- 347
- 348

349 **Permanently putting into effect modifications and innovations**

A substantial majority of respondents (almost three quarters of those from HICs and more than four-350 fifths of those from LMICs) stated that many of the modifications and innovations to operating 351 352 procedures implemented during the pandemic should be permanently put into effect (Table S 12), particularly in the areas of meeting logistics and frequency, procedures for protocol review and 353 354 approval, and training of ethics review committee members in new or modified procedures (Table S 355 13). Several participants argued in their text responses that virtual online meetings should be a 356 permanent feature of ERC operations, as they increase efficiency and preclude many of the 357 disadvantages of face-to-face meetings. Another recommendation was to enable the integration of ad 358 hoc committees during times of increased demand. Similarly, respondents emphasized the relevance of 359 facilitating the incorporation of new expert members to the ERCs as required. However, 20% of 360 participants from HICs and 50% of those from LMICs indicated that their ERCs had no support to

It is made available under a CC-BY 4.0 International license . Research ethics review during the COVID-19 pandemic: An international study

Page 20 of 46

- 361 permanently implement modifications or innovations established during the COVID-19 pandemic
- 362 (Table S 14).
- 363

364 **Policies, procedures, and guidelines for public health emergencies**

365 It is noteworthy that almost half of respondents from HICs and three-quarters of participants from

- 366 LMICs indicated that their ERCs did not have internal policies, procedures, or guidelines before the
- 367 pandemic that could orient members regarding the functioning of the committees during PHEs (Table
- 368 **S 15**). Regarding the use of internal guidelines, some ERCs adapted existing documents, while others
- 369 developed entirely new procedures. In the absence of specific internal guidelines, some SOPs explicitly
- 370 privileged expedited review during health crises.
- 371
- 372 In contrast to the widespread absence of internal guidelines, the ERCs of one quarter of respondents
- 373 from HICs and of almost half of those from LMICs used external guidelines not developed by their
- 374 committees to govern their operation during the pandemic (Table S 16). Members of several
- 375 committees referred to publicly available national and international guidelines. A selection of the most
- 376 consulted documents appears in **Box 2**.
- 377

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 21 of 46

378

Box 2. National and international external guidelines* that survey respondents reported were used by
 their ERCs to manage operations during the COVID-19 pandemic

381

International Health Organizations

- Council for International Organizations of Medical Sciences, & World Health Organization (2016). International Ethical Guidelines for Health-related Research Involving Humans (Fourth Ed.). Council for International Organizations of Medical Sciences. <u>https://doi.org/10.56759/rgx17405</u>
- Pan-American Health Organization (2020). Guidance for ethics oversight of COVID-19 research in response to emerging evidence. <u>https://iris.paho.org/handle/10665.2/53021</u>
- Pan-American Health Organization (2020). Guidance and strategies to streamline ethics review and oversight of COVID-19-related research. <u>https://iris.paho.org/handle/10665.2/52089</u>
- Pan-American Health Organization (2020). Template and operational guidance for the ethics review and oversight of COVID-19-related research. <u>https://iris.paho.org/handle/10665.2/52086</u>
- Pan-American Health Organization (2022). Catalyzing ethical research in emergencies. Ethics guidance, lessons learned from the COVID-19 pandemic, and pending agenda. <u>https://iris.paho.org/handle/10665.2/56139</u>
- Red de América Latina y el Caribe de Comités Nacionales de Bioética United Nations Educational, Scientific and Cultural Organization (UNESCO) (2020). Ante las investigaciones biomédicas por la pandemia de enfermedad infecciosa por coronavirus Covid-19. <u>https://redbioetica.com.ar/wp-content/uploads/2020/03/Declaracion-RED-ALAC-CNBS-Investigaciones-Covid-19.pdf</u>
- World Health Organization (2016). Guidance for managing ethical issues in infectious disease outbreaks. World Health Organization. <u>https://apps.who.int/iris/handle/10665/250580</u>
- World Health Organization (2020). Key criteria for the ethical acceptability of COVID-19 human challenge studies. https://apps.who.int/iris/handle/10665/331976
- World Health Organization (2020). Guidance for research ethics committees for rapid review of research during public health emergencies. <u>https://apps.who.int/iris/handle/10665/332206</u>
- World Health Organization (2020). Ethical standards for research during public health emergencies: distilling existing guidance to support COVID-19 R&D. <u>https://apps.who.int/iris/handle/10665/331507</u>

Bioethics centres

- Nuffield Council of Bioethics (2020). Ethical considerations in responding to the COVID-19 pandemic.
 <u>https://www.nuffieldbioethics.org/assets/pdfs/Ethical-considerations-in-responding-to-the-COVID-19-pandemic.pdf</u>
- The Hastings Center: Berlinger N *et al.* (2020). Ethical Framework for Health Care Institutions Responding to Novel Coronavirus SARS-CoV-2 (COVID-19). Guidelines for Institutional Ethics Services Responding to COVID-19. https://www.thehastingscenter.org/ethicalframeworkcovid19/

Scientific publications mentioned by respondents

• Saxena et al. (2019). Ethics preparedness: facilitating ethics review during outbreaks - recommendations from an expert panel. <u>https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-019-0366-x</u>

National guidelines

Argentina

 Resolución 908/2020. Ministerio de Salud de Argentina: <u>https://www.argentina.gob.ar/normativa/nacional/resoluci%C3%B3n-908-2020-337359/texto</u>

Brazil

Normativas da Comissão Nacional de Ética em Pesquisa: <u>http://conselho.saude.gov.br/normativas-conep?view=default</u>

Costa Rica

 Consejo Nacional de Investigación en Salud de Costa Rica (CONIS) (2020). COMUNICADO 2: Recomendaciones para realizar investigación biomédica durante el periodo de la emergencia sanitaria por COVID-19 en Costa Rica. https://www.ministeriodesalud.go.cr/gestores_en_salud/conis/circulares/comunicado_cec_oac_oic_20082020.pdf

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 22 of 46

udor
Comité Nacional de Ética de la Investigación en Salud de El Salvador (2015). Manual de procedimientos operativos estándar para comités de ética de la investigación en salud. <u>https://www.cneis.org.sv/wp-content/uploads/2018/07/MANUAL-CNEIS.pdf</u>
Indian Council of Medical Research (2017). National ethical guidelines for biomedical and health research involving human participants. <u>https://ethics.ncdirindia.org/asset/pdf/ICMR_National_Ethical_Guidelines.pdf</u> Indian Council of Medical Research (2020).National guidelines for ethics committees reviewing biomedical & health research during COVID-19 pandemic. <u>https://main.icmr.nic.in/sites/default/files/guidelines/EC_Guidance_COVID19_06_05_2020.pdf</u>
Kenya Medical Research Institute Scientific and Ethics Review Unit (2019). KEMRI SERU guidelines for the conduct of research during the covid-19 pandemic in Kenya. <u>https://www.kemri.go.ke/wp-content/uploads/2019/11/KEMRI-SERU_GUIDELINES-FOR-THE-CONDUCT-OF-RESEARCH-DURING-THE-COVID_8-June-2020_Final.pdf</u>
a Garis Panduan Pengurusan COVID-19 di Malaysia No.5 [COVID-19 Management Guidelines in Malaysia No.5] (2020). Ministry of Health of Malaysia. <u>https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm</u>
<i>a</i> Government of Pakistan National COVID Command and Operation Center (NCOC) Guidelines (2020). [No longer available, as NCOC ceased operations on April 1, 2022)]
frica Department of Health, Republic of South Africa (2015). Ethics in Health Research: Principles, Processes and Structures (2d Ed). <u>https://www.sun.ac.za/english/research-innovation/Research-</u> <u>Development/Documents/Integrity%20and%20Ethics/DoH%202015%20Ethics%20in%20Health%20Research%20-</u> <u>%20Principles,%20Processes%20and%20Structures%202nd%20Ed.pdf</u>
<i>Torea</i> Government of the Republic of Korea (2014). Bioethics and Safety Act (Act No. 12844). <u>https://elaw.klri.re.kr/eng_mobile/viewer.do?hseq=33442&type=part&key=36</u>
Kingdom United Kingdom Health Departments / Research Ethics Service (2022). Standard Operating Procedures for Research Ethics Committees (Version 7.6). https://www.hra.nhs.uk/documents/3090/RES_Standard_Operating_Procedures_Version_7.6_September_2022_Final.pdf . [In particular, several respondents from the UK mentioned Section 9 of this document, which addresses expedited review in situations such as public health emergencies.] Health Research Authority (2020). https://www.hra.nhs.uk/approvals-amendments/ Health Research Authority (2020). https://www.hra.nhs.uk/covid-19-research/covid-19-guidance-sponsors-sites-and-researchers/ Department of Health and Social Care (2020). Coronavirus (COVID 10): notification to organizations to share

- 386 Respondents stated that the workload of ERC members increased considerably during the pandemic,
- both because of the increase in the number of protocols reviewed and due to the urgency that the

382383384

It is made available under a CC-BY 4.0 International license.

Research ethics review during the COVID-19 pandemic: An international study

Page 23 of 46

388	approval of COVID-19-related studies demanded. More than half of participants indicated that the
389	volume of protocols received for review increased, both for studies assigned to delegated / expedited
390	review, and for protocols that underwent full review (Table S 17). The increase in the volume of
391	protocols had unexpected consequences. For example, in one HIC, the number of applicants who were
392	summoned to discuss their protocols with ERCs in online meetings increased proportionally to the
393	escalation in the volume of protocols submitted. In another case, ERC members were burdened with
394	additional tasks such as working closely with the investigators of rejected COVID-19 protocols to
395	improve their applications until these could be approved.
396	
397	In terms of the time it took ERCs to process and approve protocols during the pandemic, respondents
398	confirmed in their text answers that the turnaround time for ERC review was markedly shortened, from

399 weeks or even months to just a few days. In general, more than half of survey participants indicated

400 that, before the pandemic, the duration of the review process, from the time of initial submission to full

401 approval, was between three and eight weeks (**Table S 18**). In contrast, during the pandemic, this

402 process was substantially reduced to less than two weeks for both delegated / expedited review and full

403 review. However, this decrease was more pronounced in HICs than in LMICs (Table S 19).

404 Unsurprisingly, the approval of COVID-19-related research protocols was faster than that of non-

405 COVID-19 studies. More than two-thirds of respondents indicated that delegated / expedited review of

406 COVID-19-related protocols took less than five weeks; this was the case for more than half of full

407 reviews. The process was longer in LMICs, though (Table S 20). Conversely, protocol review was

408 slightly longer for non-COVID-19 studies, except in the case of full reviews in LMICs, which

409 participants reported took between three and more than 12 weeks (Table S 21).

It is made available under a CC-BY 4.0 International license.

Research ethics review during the COVID-19 pandemic: An international study

Page 24 of 46

411 **Presence of external pressure on ERCs**

412 While only 14% of respondents from HICs reported that their ERCs were subjected to different types 413 of external pressure to both approve and reject research protocols, one third of participants from LMICs 414 (34%) faced such a challenge (Table S 22). The most frequent perceived demand involved pressures to 415 rush studies through the review process at the expense of proper examination and ethical oversight. This was especially evident in the case of COVID-19 vaccine clinical trials. Some participants 416 417 highlighted their defense of the autonomy of their ERCs in the face of external influences by using, for 418 example, research policies developed and implemented specifically for the pandemic as a tool for 419 transparent decision-making and as a safeguard against external pressures. One ERC successfully 420 resisted government pressure to approve a research protocol related to a domestic PCR test, human 421 trials of locally developed ventilators, and a placebo-controlled vaccine trial proposed despite the 422 existence of six emergency-authorized vaccines and ongoing mass vaccination. 423 424 While some respondents acknowledged that entities such as national governments were understandably 425 impatient for preventive, diagnostic, and therapeutic measures to combat the pandemic, they still 426 emphasized the need for proper and thorough review of research protocols. One respondent stated that institutional authorities that favoured or sponsored certain studies sought their immediate approval and 427 428 considered ERCs as inconvenient hindrances to achieve this goal. Several participants described 429 instances in which ERCs, particularly in LMICs, received pressure to approve alternative medicine 430 clinical trials.

- 431
- 432
- 433

It is made available under a CC-BY 4.0 International license .

Research ethics review during the COVID-19 pandemic: An international study

Page 25 of 46

434 Types of COVID-19 protocols reviewed by ERCs

- 435 Given the range of challenges brought about by the COVID-19 pandemic, it was interesting to
- 436 determine the proportion of protocols received by ERCs according to the research area in which they
- 437 could be classified, namely, diagnostics, therapeutics, vaccines, pharmacovigilance, or other topics
- 438 such as behavioural research. Our results suggest that between one-half and two-thirds of ERCs
- 439 received from one to 10 studies in each area (Table 5). In other words, all areas of COVID-19 research
- 440 were covered in these protocols in ERCs of both HICs and LMICs. However, it must be noted that
- 441 between one-third and one-half of respondents could not classify the protocols received by their ERCs
- 442 (perhaps due to not tracking such information).

 Table 5. Number of COVID-19 protocols reviewed, by type of study

446

Δ	. /	lf

	Dia	Diagnostics			Therapeutics			Vaccines			Pharmacovigilance			Other						
	HICs LMICs		HICs LMICs		HICs LMICs		HICs		LMICs		HICs		LMICs							
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0	10	22.2	8	25.0	10	19.6	8	22.9	10	22.2	8	24.2	10	27.8	7	25.9	9	20.5	7	20.0
1 to 10	29	64.4	19	59.4	27	52.9	17	48.6	24	53.3	16	48.5	20	55.6	13	48.1	23	52.3	16	45.7
11 to 20	5	11.1	3	9.4	5	9.8	3	8.6	4	8.9	3	9.1	4	11.1	3	11.1	4	9.1	3	8.6
21 to 30	0	0.0	2	6.3	0	0.0	2	5.7	0	0.0	2	6.1	0	0.0	1	3.7	0	0.0	1	2.9
> 30	1	2.2	0	0.0	1	2.0	0	0.0	1	2.2	0	0.0	1	2.8	0	0.0	1	2.3	0	0.0
No response	0	0.0	0	0.0	8	15.7	5	14.3	6	13.3	4	12.1	1	2.8	3	11.1	7	15.9	8	22.9
TOTAL	45	100	32	100	51	100	35	100	45	100	33	100	36	100	27	100	44	100	35	100

It is made available under a CC-BY 4.0 International license .

Page 27 of 46

449 **Prioritization of protocols for ethics review**

450 Overwhelmingly, and as expected, participants reported that their ERCs considered COVID-19-related 451 protocols urgent and thus prioritized their review and approval over that of others, particularly in terms 452 of expediting the review of these studies and privileging their discussion during committee meetings. 453 More than three quarters of respondents from HICs and almost two-thirds of those from LMICs 454 indicated that their ERCs gave priority to COVID-19-related studies (Table S 23). In fact, in one case, 455 an ERC stopped reviewing non-COVID-19-related protocols altogether. Some ERCs gave precedence 456 to the review of COVID-19-related studies according to the priorities determined by their national 457 governments. Others were assigned studies by an *ad hoc* national entity that triaged the research 458 protocols. Interestingly, however, as shown in Table S 23, 15% of respondents from HICs and 27% of 459 those from LMICs stated that their ERCs did not give priority to pandemic-related studies.

460

461 Furthermore, our results show that almost one-third of respondents from HICs and almost half of those 462 from LMICs indicated that, for their ERCs, the review of some types of COVID-19-related studies took 463 precedence over that of others (Table S 24). In their text responses, participants explicitly mentioned 464 prioritizing clinical trials, particularly those focused on COVID-19 vaccine development and safety 465 monitoring; studies related to therapeutic agents for the treatment of COVID-19; protocols about 466 diagnostics and prognostic factors; epidemiological studies, including those related to the natural 467 history of COVID-19 and serosurveillance; and research affecting public health policy. In the case of 468 one ERC in a HIC with very low infection rates resulting from successful public health measures, 469 priority was given to vaccine trials and observational research on vaccine monitoring and community 470 incidence.

It is made available under a CC-BY 4.0 International license .

Page 28 of 46

471 Membership of ERCs during the pandemic

One of the main challenges that ERCs worldwide faced during the pandemic was making certain that the number and expertise of their members enabled the efficient operation of the committees under such demanding circumstances. Most survey respondents indicated that their ERCs were able to ensure quorum (80% of participants from HICs, but only 60% of those from LMICs); however, one-third of respondents from LMICs stated that quorum in their ERCs was infrequently met (**Table S 25**). Twothirds of participants from HICs and three quarters of those from LMICs reported that their committees had taken measures to ensure continuity of adequate review of research protocols in case existing

members became unavailable due to the pandemic (Table S 26).

480

479

481 ERCs in both HICs and LMICS did invite new members or appointed alternate ones to ensure quorum 482 and inclusion of individuals with appropriate expertise. Yet, consulting expert non-members seems to 483 have been preferred to incorporating individuals to the committee. Only 13% of respondents from HICs 484 and 24% of those from LMICs indicated that their ERCs had added new members to accelerate 485 protocol review during the pandemic (Table S 27). Similarly, 11% of participants from HICs and 37% of those from LMICs added new members with specific expertise (Table S 28). In contrast, almost 486 487 one-third of individuals from HICs, but close to two-thirds of those from LMICs, stated that their 488 committees had consulted expert non-members to address novel areas of research or provide enhanced 489 scrutiny of research protocols (Table S 29). In their text responses, participants expressed that, in some 490 cases, ERCs incorporated new members available at quick notice and who were comfortable with the 491 use of online platforms for meetings and protocol review. A similar approach consisted of integrating 492 virtual ad hoc committees solely to review COVID-19-related-protocols. For some ERCs, national

It is made available under a CC-BY 4.0 International license .

Page 29 of 46

493	legislation complicated getting additional support or adding new members. Another factor complicating
494	the integration of ERCs was that clinical responsibilities of individuals directly in the care of COVID-
495	19 patients soared, hindering their participation in committee meetings. One participant reported that
496	some ERC members could not fulfill their duties in the ERC because they had become highly sought-
497	after "media celebrity" experts.

498

499 Survey respondents suggested that it would be worthwhile to assess the psychological and emotional 500 challenges that ERC members faced by having to evaluate protocols using new, unfamiliar procedures 501 under extreme pressure. Also, it is worth reiterating that, according to several participants, many ERC 502 members, particularly older ones, deplored the loss of features common to face-to-face meetings, such 503 as a warmer, more informal and welcoming environment that favoured interpersonal interactions. Other 504 respondents expressed their desire for constructive and supportive feedback and for more appreciative 505 and generous gestures of gratitude for the extraordinary efforts of ERCs. However, a few participants 506 considered that being able to respond in a useful way to a public health crisis as ERC members was 507 very gratifying and validating.

508

509 National and international collaboration

While ~40% of respondents from HICs and LMICs reported the presence of national and international collaboration among ERCs to standardize emergency operations and procedures during the pandemic, almost one-third of participants from HICs were unsure about the existence of such collaboration (Table S 30). Almost half of respondents from HICs, but more than two-thirds of those from LMICs, indicated that their ERCs did not have strategies to harmonize multiple review processes (Table S 31).

It is made available under a CC-BY 4.0 International license .

Page 30 of 46

515	Most participants (55% of those from HICs and 63% of those from LMICs) reported that their ERCs
516	relied on established procedures to recognize and validate research protocol reviews conducted by
517	other committees (Table S 32). About one half of respondents from HICs, but almost two-thirds of
518	those from LMICs, affirmed that their ERCs collaborated with scientific committees that pre-reviewed
519	or prioritized pandemic-related research protocols (Table S 33).
520	
521	Almost 50% of participants from HICs, but little more than a third of those from LMICs, reported the
522	presence of centralized ethics review of research protocols for multicentre studies related to COVID-19
523	(Table S 34). Conversely, one-third of respondents from HICs, but more than two-thirds of those from
524	LMICs, stated that their ERCs did not consider the formation of Joint Scientific Advisory Committees,
525	Data Safety Review Committees, Data Access Committees, or a Joint Ethics Review Committee with
526	representatives of ethics committees of all institutions and countries involved in COVID-19-related
527	research (Table S 35).
528	
529	In their text responses, participants noted the need for better inter-ERC collaboration and
530	communication at the national and international levels to share successful strategies and avoid effort
531	duplication. A case of very successful national inter-ERC collaboration is worth mentioning.
532	Respondents from one particular LMIC stated that, given the critical absence of the national entity
533	responsible for health research ethics during the pandemic, ERCs throughout the country joined forces
534	to create an <i>ad hoc</i> spontaneous informal national network of all ERC chairs and co-chairs (it also
535	included members of the national drug regulator) to strengthen mutual support, enhance
536	communication among ERCs, identify best practices, and share academic and ethics resources.

It is made available under a CC-BY 4.0 International license .

537 **DISCUSSION**

538

539	ERCs faced considerable challenges during the COVID-19 pandemic. Demands were placed on
540	them to urgently review an increased volume of protocols while maintaining rigour, all under
541	suboptimal conditions and uncertainty. Yet, our findings suggest ERCs reviewed a greater volume of
542	protocols and did so faster than before the pandemic. Against this backdrop, our results also reveal that,
543	despite billions of dollars having been invested into the R&D ecosystem to support the COVID-19
544	research response, little to no additional resources were directed to ERCs to support and/or expedite
545	their functions. This should be particularly sobering for those who raise complaints about ERCs being
546	an "obstacle" to research [12–15]. It may also help to explain other challenges experienced by ERCs
547	during the pandemic, such as the absence of internal policies or guidelines for adapting to a PHE, the
548	collateral damage sustained from deprioritizing non-COVID-19 protocols, and the pressures felt to rush
549	protocols through review.

550

551 Our finding that ERCs wish to sustain many of the modifications made to their operations during the 552 COVID-19 pandemic should be interpreted in light of the fact that ERCs also report having received 553 little or no support during the COVID-19 pandemic as well as exiguous support for the maintenance of 554 any modifications they wish to make permanent into the future. If it is expected that our research ethics 555 ecosystem learns from this experience and enhances operations for future threats, it is difficult to see 556 how this will be possible without significant investment. While no one seems to disagree that the 557 research ethics ecosystem should strive for greater efficiency and collaboration, especially during 558 PHEs, investments are required to achieve these aims. Simply put, the experience of ERCs during the

It is made available under a CC-BY 4.0 International license .

559 COVID-19 pandemic, while herculean in many respects, was a function of necessity and is unlikely to560 be sustainable.

561

562 Extant literature reporting the challenges faced by ERCs during the COVID-19 pandemic is scant and 563 tends to be limited to the early phases of this PHE. Most studies published on this topic are confined to 564 single countries or geographical regions, with only one study including 14 countries in Africa, Asia, 565 Australia, and Europe[16]. Several of these contributions focus exclusively on one ERC, usually 566 associated with an academic or health care institution. The literature includes descriptions of ERC 567 operations during the pandemic in Central America and the Dominican Republic [17], China [18], 568 Ecuador [19], Egypt [20], Germany [21], India [22–24], Iran [10], Ireland [25], Kenya [26], 569 Kyrgyzstan [27], Latin America [28], the Netherlands [29], Pakistan [30], South Africa [31,32], Turkey 570 [33], and the United States [34–36]. Most of these studies reported results from surveys, interviews, 571 focus groups, and documentary analysis, including review of research protocols, ERC meeting minutes, 572 and existing SOPs. Participants usually consisted of ERC chairpersons and members, clinical and 573 biomedical researchers, institutional representatives, and laypeople. Most studies based on surveys and 574 interviews included fewer than 30 respondents, with only some having more than 100 participants. 575 576 Our findings agree with this literature. Given that our study is truly global in scope, it considerably 577 broadens what is known about the operation of ERCs during the COVID-19 pandemic and clears a path

578 towards greater consensus on strategies to prepare for and respond during future PHEs.

It is made available under a CC-BY 4.0 International license .

Page **33** of **46**

580	In this literature, several studies emphasize the lack of support and resources to operate during the
581	pandemic. The vast majority of ERCs made numerous modifications to their SOPs. In particular, the
582	use of online platforms for ERC meetings and for protocol review was ubiquitous. However, ERC
583	members across studies pointed out several disadvantages of such platforms, including lack of
584	familiarity and technical know-how, particularly in the case of more senior members of the committees.
585	Only a few institutions provided training, equipment, and technical support for the use of these online
586	platforms. Consistent with our findings, almost no ERCs in these studies reported having internal
587	policies, procedures, or guidelines to operate during a PHE. National regulations on this topic, where
588	available, were often unclear, contradictory, rapidly changing, vague, or difficult to interpret.
589	Conversely, several ERCs availed themselves of international guidelines (Box 2), in particular those
590	prepared by WHO [37–40] and PAHO [41–44].
591	
592	In terms of changes in workload, all ERCs in the studies mentioned earlier experienced a dramatic
593	increase in the number of COVID-19-related protocols received, which had to be reviewed very
594	quickly in the face of pressure from researchers, institutions, governments, and the media for expedited
595	approvals. The surge in the volume of protocols, along with shortened timelines for turnaround,
596	severely strained ERC members' ability to conduct rigorous, thorough, high-quality assessments.
597	Despite feeling overwhelmed, ERC members participating in these studies managed to fulfill their
598	responsibilities, sometimes at great personal cost.
599	
600	Given the urgency to examine and approve an ever-increasing number of COVID-19 research

601 protocols, the studies report several strategies implemented by ERCs worldwide to prioritize their

It is made available under a CC-BY 4.0 International license .

Page 34 of 46

review. This frequently meant that the assessment of non-COVID-19-related studies was postponed or
even abandoned. Similarly, non-interventional COVID-19 protocols were given secondary importance.
Prioritization of COVID-19 protocols by type of study was rare.

605

Despite numerous staffing challenges, most ERCs in the studies examined were able to ensure quorum. In some cases, their institutions provided training sessions to update committee members on the rapidly changing landscape of basic and clinical knowledge about COVID-19. A less frequently used approach was to incorporate new members with relevant expertise into the ERCs. One common strategy across different countries was the integration of *ad hoc* committees focused exclusively on the review of COVID-19 -related protocols.

612

The topic of centralized review of pandemic-related research is rather contentious in this literature. While some studies report ERC members favouring such an approach, others consider that a single national ERC in charge of PHE-specific ethics review is bound to be unsuccessful due to the importance of local context in responding to PHEs. In Ecuador, forcing researchers to submit their protocols to a seven-member centralized *ad hoc* ERC caused considerable delays in the approval process and instead severely impeded the execution of COVID-19-related studies [19].

619

As shown in our results, in some countries ERCs strengthened collaboration networks during the
pandemic. A notable case was the creation of a spontaneous, informal, *ad hoc* group in South Africa—
the Research Ethics Support in COVID-19 Pandemic (RESCOP) —by ERC chairpersons and members
as a response to the lack of national ethics guidance and the unexpected critical absence of the National

It is made available under a CC-BY 4.0 International license .

- Health Research Ethics Council at the most crucial moment in the pandemic [32]. This example
- highlights the clear need for national governance and oversight for research ethics to ensure
- 626 accountability and responsiveness of ERCs [45].
- 627
- 628 A common topic of concern across ERCs in several countries was the set of unique challenges to
- 629 obtaining informed consent during the pandemic, especially in the case of patients unable to give
- 630 consent, such as those who were severely ill, isolated, or in the intensive care unit. Thus, it was
- 631 necessary to find innovative alternative strategies to obtain consent.
- 632
- 633

It is made available under a CC-BY 4.0 International license .

634 **RECOMMENDATIONS**

635

636 **Box 3.** Recommendations to strengthen the resiliency of ERCs during future public health emergencies.

637

•

Increase an	nd assign	an adequate	proportion of the	budgets of ERCs for:
			proportion or the	

- Their continued operation during PHEs, especially in terms of online teleconferencing and review platforms
- Sustaining select modifications and innovations designed and implemented during PHEs
- Increase awareness of the value of ERCs in the research and development (R&D) ecosystem as a means of protecting research participants, ensuring social value, and promoting public trust in research outputs, rather than as a bureaucratic nuisance
- Evaluate the success or failure of modifications and innovations designed and implemented during PHEs
- Develop a "first aid kit" for each ERC that includes:
 - Existing external guidelines for committee operation during a PHE
 - Internal contingency plans designed by the ERC or its home institution that adapt existing external guidelines to local contexts
 - A directory of expert non-members available for consultation
 - Easy-to-follow checklists that incorporate the essential elements needed to function during a PHE
- Familiarize ERC members with the "first aid kit" through periodic capacity building activities
- Consider the psychological and emotional challenges that ERC members face during PHEs
- Devise strategies to defend and safeguard ERCs' autonomy against external pressures
- Promote national and regional collaboration networks of ERCs that strengthen their resiliency during PHEs
- Facilitate collaboration between ERCs and scientific committees
- 638 639

640 LIMITATIONS AND STRENGTHS

- 642 In terms of the limitations of our study, it would have been desirable to include participants
- 643 from more countries, and a larger number of respondents from each country. It was probably difficult
- 644 to reach a higher response rate due to "pandemic fatigue". Non-native English speakers, especially in
- 645 LMICs, may have excluded themselves from our survey. Absent or unreliable internet access could

It is made available under a CC-BY 4.0 International license .

Page **37** of **46**

646	have limited the participation of some participants, particularly in LMICs. The number of ERC
647	members that provided ethics review for health care facilities was relatively low. Despite the
648	anonymity of their answers, respondents may have been reluctant to share specific instances of external
649	pressures impinging upon their ERCs. The large number of participants from the UK (93 out of 281)
650	likely skewed the results from HICs, and from experiences in the UK in particular.
651	
652	We chose to present our results descriptively and did not perform any analytic tests for statistically
653	significant differences in responses. This was because we were unable to determine a denominator, so
654	we could not meet the requirements for many significance tests. Non-parametric tests could have been
655	used, but we think reporting statistical significance in this context would not be informative. Non-
656	response bias could also influence our results. This could be non-differential in its effects as our results
657	cohere with the literature thus far reported.
658	
659	To our knowledge, this is the first examination at a global level of the challenges faced by ERCs during
660	the COVID-19 pandemic, and the strategies used to address them. Also, our study compares for the
661	first time several dimensions of the operation of ERCs during the pandemic between committees in
662	HICs and those in LMICs. All WHO regions were represented in our study, as participants from 48
663	countries (19 HICs and 29 LMICs) responded to our survey. There was an adequate balance in terms of
664	the sex / gender of respondents. Furthermore, the ample experience of the study participants as ERC
665	members (two thirds of respondents had six or more years of experience in this role) strengthens the
666	generalizability of our findings. The recommendations suggested by the study participants are quite

It is made available under a CC-BY 4.0 International license .

Page 38 of 46

relevant to combating future public health emergencies. In general, all these strengths give credence tothe validity, reliability, and accuracy of our results.

669

670 ACKNOWLEDGEMENTS

671

672 We are very grateful to all the members of ethics review committees who participated in our 673 survey. We also want to express our gratitude to Andreas Reis and Katherine Littler of the Health 674 Ethics and Governance Unit, World Health Organization, and to the following members of the World 675 Health Organization COVID-19 Ethics and Governance Working Group, for their inputs on the survey 676 instrument and manuscript: Aasim Ahmad, Thalia Arawi, Caesar Atuire, Oumou Bah-Sow, Anant Bhan, Ingrid Callies, Angus Dawson, Jean-François Delfraissy, Ezekiel Emanuel, Ruth Faden, Tina 677 678 Garanis-Papadatos, Prakash Ghimire, Dirceu Greco, Calvin Ho, Patrik Hummel, Zubairu Iliyasu, 679 Mohga Kamal-Yanni, Sharon Kaur, So Yoon Kim, Sonali Kochhar, Ruipeng Lei, Ahmed Mandil, 680 Julian März, Ignacio Mastroleo, Roli Mathur, Signe Mežinska, Ryoko Miyazaki-Krause, Keymanthri 681 Moodley, Suerie Moon, Michael Parker, Carla Saenz, G. Owen Schaefer, Ehsan Shamsi-Gooshki, 682 Jerome Singh, Beatriz Thomé, Teck Chuan Voo, Jonathan Wolff, and Xiaomei Zhai. 683 684 This project was funded by a Canadian Institutes of Health Research grant (#C150-2019-11). 685

It is made available under a CC-BY 4.0 International license .

Page **39** of **46**

687 **REFERENCES**

689	1.	Aarons D. Addressing the challenge for expedient ethical review of research in disasters and
690		disease outbreaks. Bioethics. 2019;33: 343-346. doi:10.1111/bioe.12543
691	2.	Alirol E, Kuesel AC, Guraiib MM, De la Fuente-Núñez V, Saxena A, Gomes MF. Ethics review
692		of studies during public health emergencies - The experience of the WHO ethics review
693		committee during the Ebola virus disease epidemic. BMC Med Ethics. 2017;18: 1-12.
694		doi:10.1186/s12910-017-0201-1
695	3.	Council for International Organizations of Medical Sciences, World Health Organization.
696		International Ethical Guidelines for Health-related Research Involving Humans. Fourth Ed.
697		Geneva: Council for International Organizations of Medical Sciences; 2016.
698	4.	Schopper D, Upshur R, Matthys F, Singh JA, Bandewar SS, Ahmad A, et al. Research ethics
699		review in humanitarian contexts: The experience of the independent ethics review board of
700		Médecins Sans Frontières. PLoS Med. 2009;6: 1-6. doi:10.1371/journal.pmed.1000115
701	5.	Schopper D, Ravinetto R, Schwartz L, Kamaara E, Sheel S, Segelid MJ, et al. Research ethics
702		governance in times of Ebola. Public Health Ethics. 2017;10: 49-61. doi:10.1093/phe/phw039
703	6.	Tansey CM, Herridge MS, Heslegrave RJ, Lavery J V. A framework for research ethics review
704		during public emergencies. Can Med Assoc J. 2010;182: 1533-1537. doi:10.1503/cmaj.090976
705	7.	Canadian Institutes of Health Research, Natural Sciences and Engineering Council of Canada,
706		Social Sciences and Humanities Research Council. Tri-Council Policy Statement: Ethical
707		Conduct for Research Involving Humans. 2018. Available: https://ethics.gc.ca/eng/tcps2-
708		eptc2_2018_chapter6-chapitre6.html#d

It is made available under a CC-BY 4.0 International license .

Page 40 of 46

709	8.	London AJ.	Kimmelman J	. Against r	bandemic resea	rch exceptiona	lism. Science	(1979)
107	0.	Longon 1 is		· · · · · · · · · · · · · · · · · · ·	Junaonnio resea	i on onceptiona		(1 / / /

710 2020;368: 476–477. doi:10.1126/science.abc1731

- 9. Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical considerations
- for vaccination programmes in acute humanitarian emergencies. Bull World Health Organ.
- 713 2013;91: 290–297. doi:10.2471/BLT.12.113480
- 10. Hashemi A, Bahmani F, Tehrani SS, Forouzandeh M, Koohpayehzadeh J, Ashrafi M, et al.
- 715 Ethical considerations and interdisciplinary approach to research on COVID-19 pandemic: The
- response of Iran University of Medical Sciences. Med J Islam Repub Iran. 2020;34: 1–4.

717 doi:10.34171/mjiri.34.87

- 11. Lencucha R, Neupane S. The use, misuse and overuse of the "low-income and middle-income
 countries" category. BMJ Glob Health. 2022;7. doi:10.1136/bmjgh-2022-009067
- Schneider CE. The Censor's Hand: The Misregulation of Human-Subject Research. 1st edition.
 Cambridge, Massachusetts: The MIT Press; 2015.
- 13. Kotsis S V., Chung KC. Institutional review boards: What's old? what's new? what needs to
- 723 change? Plast Reconstr Surg. 2014;133: 439–445. doi:10.1097/01.prs.0000436846.00247.73
- 14. Stryjewski TP, Kalish BT, Silverman B, Lehmann LS. The Impact of Institutional Review
- 725 Boards (IRBs) on clinical innovation: A survey of investigators and IRB members. J Empir Res
- 726 Hum Res Ethics. 2015;10: 481–487. doi:10.1177/1556264615614936
- 15. Whitney SN. Institutional review boards: A flawed system of risk management. Res Ethics.
- 728 2016;12: 182–200. doi:10.1177/1747016116649993

Page 41 of 46

729	16.	Bauer A, Eskat A, Ntekim A, Wong C, Eberle D, Hedayati E, et al. How COVID-19 changed
730		clinical research strategies: a global survey. J Int Med Res. 2022;50.

- 731 doi:10.1177/03000605221093179
- 17. Canario Guzmán JA, Orlich J, Mendizábal-Cabrera R, Ying A, Vergès C, Espinoza E, et al.
- 733 Strengthening research ethics governance and regulatory oversight in Central America and the
- 734 Dominican Republic in response to the COVID-19 pandemic: a qualitative study. Health Res
- 735 Policy Syst. 2022;20. doi:10.1186/s12961-022-00933-z
- 736 18. Zhang H, Shao F, Gu J, Li L, Wang Y. Ethics Committee Reviews of Applications for Research
 737 Studies at 1 Hospital in China During the 2019 Novel Coronavirus Epidemic. JAMA. 2020;323:
 738 1844–1846. doi:10.1001/jama.2020.3786
- Sisa I, Mena B, Teran E. The negative impact of ad hoc committees for ethical evaluation: The
 case of COVID-19-related research in Ecuador. Dev World Bioeth. 2021;21: 3–6.
- 741 doi:10.1111/dewb.12307
- 20. Marzouk D, Sharawy I, Nakhla I, El Hodhod M, Gadallah H, El-Shalakany A, et al. Challenges
- 743 During Review of COVID-19 Research Proposals: Experience of Faculty of Medicine, Ain
- 744 Shams University Research Ethics Committee, Egypt. Front Med (Lausanne). 2021;8: 715796–
- 745 715804. doi:10.3389/fmed.2021.715796
- 746 21. Faust A, Sierawska A, Krüger K, Wisgalla A, Hasford J, Strech D. Challenges and proposed
- solutions in making clinical research on COVID-19 ethical: a status quo analysis across German
- research ethics committees. BMC Med Ethics. 2021;22. doi:10.1186/s12910-021-00666-8

It is made available under a CC-BY 4.0 International license .

Page 42 of 46

749	22.	Joshi SG, Safai AA, Barve SS. Experience of the selected Ethics Committee of Pune city
750		regarding the review of COVID-19 protocols during the pandemic. Perspect Clin Res. 2023;14:
751		43-44. doi:10.4103/picr.picr_2_22
752	23.	Kadam A, Patil S, Sane S, Shahabuddin S, Panda S. Challenges faced by ethics committee
753		members in India during COVID-19 pandemic: A mixed-methods exploration. Indian J Med
754		Res. 2022;155: 461–471. doi:10.4103/ijmr.ijmr_1095_22
755	24.	Mukherjee S, Samajdar S, Tripathi R, Tripathi S. Functioning of Institutional Ethics Committees
756		during the COVID-19 pandemic: An opinion survey. Perspect Clin Res. 2022;13: 118-119.
757		doi:10.4103/picr.PICR_103_21
758	25.	Sheehy A, Ralph James J, Horgan M. Implementing a National Approach to Research Ethics
759		Review during a Pandemic – the Irish Experience. HRB Open Res. 2020;3: 63.
760		doi:10.12688/hrbopenres.13146.1
761	26.	Hinga A, Jeena L, Awuor E, Kahindi J, Munene M, Kinyanjui S, et al. Pandemic preparedness
762		and responsiveness of research review committees: lessons from review of COVID-19 protocols
763		at KEMRI Wellcome Trust Research Programme in Kenya. Wellcome Open Res. 2022;7: 75.
764		doi:10.12688/wellcomeopenres.17533.1
765	27.	Kudaibergenova T, Ibrahim M, Jain N, Vetra J. Documentary Assessment of the Abilities of
766		Kyrgyzstan's Research Ethics Committees During Public Health Emergency and Non-
767		Emergency Situations. J Empir Res Hum Res Ethics. 2023;18: 99–108.
768		doi:10.1177/15562646231176711

It is made available under a CC-BY 4.0 International license .

Page 43 of 46

769	28.	Palmero A, Carracedo S, Cabrera N, Bianchini A. Governance frameworks for COVID-19
770		research ethics review and oversight in Latin America: an exploratory study. BMC Med Ethics.
771		2021;22: 147-156. doi:10.1186/s12910-021-00715-2
772	29.	Ijkema R, Janssens MJPA, van der Post JAM, Licht CM. Ethical review of COVID-19 research
773		in the Netherlands; a mixed-method evaluation among medical research ethics committees and
774		investigators. PLoS One. 2021;16: e0255040. doi:10.1371/journal.pone.0255040
775	30.	Shekhani S, Iqbal S, Jafarey A. Adapting the ethical review process for COVID-19 research:
776		reviewers' perspectives from Pakistan. East Mediterr Health J. 2021;27: 1045-1051.
777		doi:10.26719/emhj.21.053
778	31.	Burgess T, Rennie S, Moodley K. Key ethical issues encountered during COVID-19 research: a
779		thematic analysis of perspectives from South African research ethics committees. BMC Med
780		Ethics. 2023;24: 11-24. doi:10.1186/s12910-023-00888-y
781	32.	Rossouw TM, Wassenaar D, Kruger M, Blockman M, Hunter A, Burgess T. Research ethics
782		support during the COVID-19 epidemic: a collaborative effort by South African Research Ethics
783		Committees. S Afr Health Rev. 2021;2021: 163–172.
784	33.	Ekmekci PE, Güner MD, Buruk B, Güneş B, Arda B, Görkey Ş. Challenges and practices arising
785		during public health emergencies: A qualitative survey on ethics committees. Dev World Bioeth.
786		2023;23: 23-33. doi:10.1111/dewb.12345
787	34.	Ford DE, Johnson A, Nichols JJ, Rothwell E, Dubinett S, Naeim A. Challenges and lessons
788		learned for institutional review board procedures during the COVID-19 pandemic. J Clin Transl
789		Sci. 2021;5: e107. doi:10.1017/cts.2021.27

It is made available under a CC-BY 4.0 International license .

Page 44 of 46

790	35.	Sisk BA, Baldwin K, Parsons M, DuBois JM. Ethical, regulatory, and practical barriers to
791		COVID-19 research: A stakeholder-informed inventory of concerns. PLoS One. 2022;17:
792		e0265252. doi:10.1371/journal.pone.0265252
793	36.	Taylor HA, Serpico K, Lynch HF, Baumann J, Anderson EE. A snapshot of U.S. IRB review of
794		COVID-19 research in the early pandemic. J Clin Transl Sci. 2021;5: e205.
795		doi:10.1017/cts.2021.848
796	37.	World Health Organization. Guidance for managing ethical issues in infectious disease
797		outbreaks. Geneva; 2016. Available: https://apps.who.int/iris/handle/10665/250580
798	38.	World Health Organization. Key criteria for the ethical acceptability of COVID-19 human
799		challenge studies 6 May 2020. 2020. Available: https://apps.who.int/iris/handle/10665/331976
800	39.	World Health Organization. Guidance for research ethics committees for rapid review of
801		research during public health emergencies. 2020. Available:
802		https://apps.who.int/iris/handle/10665/332206
803	40.	World Health Organization. Ethical standards for research during public health emergencies:
804		Distilling existing guidance to support COVID-19 R&D. Journal of Infectious Diseases. 2020.
805		Available: https://apps.who.int/iris/handle/10665/331507
806	41.	Pan-American Health Organization. Catalyzing ethical research in emergencies: Ethics
807		guidance, lessons learned from the COVID-19 pandemic, and pending agenda. 2022. Available:
808		https://iris.paho.org/handle/10665.2/56139
809	42.	Pan-American Health Organization. Template and operational guidance for the ethics review and
810		oversight of COVID-19-related research. 2020. Available:
811		https://iris.paho.org/handle/10665.2/52086

It is made available under a CC-BY 4.0 International license .

Page 45 of 46

010	10	D · ·	TT 1/1 O	•	a · 1 1					1
812	43.	Pan-American	Health Or	ganization.	Guidance and	strategies to	o streamline	ethics r	eview a	and

- 813 oversight of COVID-19-related research. 2020. Available:
- 814 https://iris.paho.org/handle/10665.2/52089
- 815 44. Pan-American Health Organization. Guidance for ethics oversight of COVID-19 research in
- 816 response to emerging evidence. 2020. Available: https://iris.paho.org/handle/10665.2/53021
- 817 45. World Health Organization. WHO tool for benchmarking ethics oversight of health-related
- 818 research with human participants (Draft). Geneva; 2022. Available:
- 819 https://www.who.int/publications/m/item/who-tool-for-benchmarking-ethics-oversight-of-
- 820 health-related-research-with-human-participants
- 821
- 822
- 823

- 824 SUPPORTING INFORMATION
- 825 S1 Appendix. Qualtrics questionnaire
- 826 S2 Appendix. Supplementary Tables
- Table S 1. World Health Organization region for which ethics review was provided
 - Table S 2. Length of experience of participants as ethics review committee members
- Table S 3. Number of ethics review committees in which participants were involved during the COVID-19 pandemic
- Table S 4. Simultaneous involvement with multiple ethics review committees
- **Table S 5.** Presence of additional support for the operation of ethics review committee during the COVID-19 pandemic
- **Table S 6.** Additional support of ethics review committee, by type
- **Table S 7.** Pre-pandemic financial planning with provisions for support of ethics review committees during a public health emergency
- **Table S 8.** Modification of existing procedures or policies
- **Table S 9.** Modified procedures and policies
- **Table S 10.** Design and implementation of new procedures and policies
- **Table S 11.** New procedures and policies

It is made available under a CC-BY 4.0 International license .

- **Table S 12.** Opinions on whether to permanently put into effect modifications or innovations to operating procedures implemented during the COVID-19 pandemic
 - **Table S 13.** Modifications or innovations to operating procedures implemented during the COVID-19 pandemic that should be permanently put into effect
- Table S 14. Presence of support to permanently implement modifications or innovations
 established during the COVID-19 pandemic
- **Table S 15.** Presence of internal policies, procedures, or guidelines
- **Table S 16.** Presence of external policies, procedures, or guidelines
 - Table S 17. Extent of change in the volume of protocols reviewed during the pandemic
- Table S 18. Time it took before the COVID-19 pandemic for research protocols to be approved,
 from the time of initial submission to full approval
 - **Table S 19.** Length of time that ethics review committee members took to complete review of research protocols during the COVID-19 pandemic
- **Table S 20.** Total time to approval of COVID-19-related research protocols
 - Table S 21. Total time to approval for non-COVID-19-related research protocols
 - **Table S 22.** Presence of external pressure on ethics review committees to approve or reject specific COVID-19 research protocols
 - Table S 23. Prioritization of COVID-19 related research over non-COVID-19-related protocols
 - Table S 24. Prioritization of some types of COVID-19-related research over others
 - Table S 25. Ensuring quorum

843

844

849

852

853

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869 870

871

874

875

876

- **Table S 26.** Presence of measures to ensure continuity of adequate review of research protocols in case existing members became unavailable due to the pandemic
- **Table S 27.** Addition of new members to accelerate protocol review during the COVID-19 pandemic
 - **Table S 28.** Addition of new members with specific expertise to address novel areas of research or provide enhanced scrutiny of research protocols during the COVID-19 pandemic
 - **Table S 29.** Consultation of expert non-members to address novel areas of research or provide enhanced scrutiny of research protocols during the COVID-19 pandemic
- **Table S 30.** National and international collaboration among ethics review committees to standardize emergency operations and procedures during the COVID-19 pandemic
- **Table S 31.** Presence of strategies to harmonize multiple review processes
- Table S 32. Reliance on established procedures to recognize and validate research protocol
 reviews conducted by other ethics committees
 - **Table S 33.** Collaboration with scientific committees that pre-reviewed or prioritized pandemicrelated research protocols
 - **Table S 34.** Presence of centralized ethics review of research protocols for multicentre studies related to COVID-19
- Table S 35. Formation of Joint Scientific Advisory Committees, Data Safety Review
 Committees, Data Access Committees, or a Joint Ethics Review Committee



Figure 1